Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
UNION INTERNATIONALE DES ASSOCIATIONS DE DÉLÉGUÉS MÉDICAUX INTERNATIONAL UNION OF MEDICAL ADVISERS ASSOCIATIONS UNIÓN INTERNACIONAL DE ASOCIACIONES DE VISITADORES MÉDICOS INTERNATIONALE VEREINIGUNG DER PHARMABERATER - VERBÄNDE INTERNATIONALE UNION DER ÄRZTEBESUCHER VEREINIGUNGEN ΔΙΕΘΝΗΣ ΕΝΩΣΗ ΣΥΛΛΟΓΩΝ ΙΑΤΡΙΚΩΝ ΕΠΙΣΚΕΠΤΩΝ UIADM PRESS RELEASE The 23rd International Congress of U.I.A.D.M. took place on 4-6/12/2009, in a time that world community confronts the biggest economic crisis after World War II and in a very competitive environment, both at a European and at an international level. The Congress examined the situation that prevails today in the sector of Drug, both internationally and in every individual country, as the circumstances have been shaped because of the global economic crisis as well. Phrmaceutical research, as it has been evolved during the last decades, has probably reached its limits regarding conventinal drugs and is oriented, in conjunction with biomedical technology, to a specialized targeting. This is the reason why we see accumulations of funds and mergers of companies, in order to support research, whose cost today is very high, and also to retain the market shares by promoting research and work positions. The accomodation from the conventional pharmaceutical access to the biomedical plarmaceutical answer is inevitable, not only in terms of economic survical, but also as a strategically planned solution for the promotion of health. The drug market is currently balanced, despite the negative symbolisms which is a certain result of mergers and high accumulation of funds. We see, however, that work positions become fewer and fewer, both internationally and in the national markets. On the other hand, the states, unable to absorb these changes, turn to measures that limit health expenses. The market compensation mechanisms that are being deceloped at a national level cannot absorb these changes, which are “imposed” socially and economically. Χαλκοκονδύλη 56 – 10432 ΑΘΗΝΑ – Τηλ.: 210-52.24.070, 210-52.35.331 – Fax: 210-52.35.331 56, Halkokondili st., Athens 10432 Hellas, Tel.: +30.210.52.24.070, +30.210-52.35.331 – Fax: +30.210-52.35.331 www.uiadm.org - e-mail: [email protected] For this reason, the states bring into play mechanistic means that only serve the budgets and the balance sheets of the states for the particular period in which the negative financial sizes appeared. We have seen such measures from time to time in various countries, but they do not have any permanent financial result: Positive or negative lists of drugs Tenders for the procurement of supplies to Hospitals and Insurance Funds Contribution of the insured persons into the medication cost O.T.C. Support of productive procedures for the generics Redecution of prices Prescription control, etc. People working in Drug often face unfair attacks and denigrations from the Media or other sectors, exactly because we serve a domain which is socially sensitive and economically demonized. The main target for these derogatory “social” refereneces is usually the Medical Adviser. Due to the nature of our profession, we are the main link that connects pharmaceutical research and technology with the practice of clinical medicine, in order to promote public health. On the other hand, we transfer our clinical observations and the everyday applications of medical pharmaceutical practice to the pharmaceutical companies, among others. This valuable link has strong scientific, sopcial and economicc bonds and is therefore by default necessary in this demarkated envirionment. Human intervention in this process is not a simple economic procedure that could be done by any technical or other means; it is the main catalyte, the feedback from research and drug titration to the simple everyday medical practice, and vice versa The continuous and objective supply of information to healthcare professionals on the rational use of drugs, the patient’s compliance with the instructions of the attending physician and the systematic monitoring of an integrated system of healthcare services can contribute decisively to the significant reduction of health expenses (by saving huge financial resources) and, what’s most important, to the limation of mistakes from the misuse of drugs that, at a large extent, are fatal for the user-patient himself. According to the Federal Institute for Drugs BfArM Germany, 160,000 people are admitted every year into the Hospitals due to drug misuse while another 20,000 die of the same cause. According to the University of Rostock, these numbers amount to 250,000 and 40,000 respectively. The general directions towards which the new Board of U.I.A.D.M will work were submitted and voted in the Congress. These directions are: Α. Contacts and establishment of cooperation and dialogue with all European and international bodies that are connected to Drug and Health, ass well as with agencies of social organizations. 1. European and international labour office 2. World Health Organization 3. European Union (Health Commissioner and Commissions, Sector of Social Affairs, etc.) 4. EFPIA and IFPIA 5. Central associations of physicians and pharmacists, etc. Β. Establishment of a single framework and certification of the profession in the European Union. C. Support and promotion of pharmacovigilance through the ongoing information and control of all of the involved parties. The 23rd Congress has elected the new Board, which is as follows: President: KONIDARIS GERASSIMOS (GR) Substitute President: WOLFGANG VOGEL (DE) Vice President: OSCAR MARIO RILO CASTRO (ES) Vice President: VASSILIADES ANDREAS (CY) Secretary General: SCHEMBRI DORIAN (MT) Sub. Secretary General: DESPINA TIRTEA (RO) Treasurer: NIKOLAIDES GREGORIS (CY) PRESS & PUBLIC RELATIONS SECRETARIAT